Danielle Antalffy
Stock Analyst at UBS
(3.40)
# 840
Out of 5,182 analysts
205
Total ratings
46.61%
Success rate
4.49%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $120 → $105 | $59.95 | +75.15% | 16 | Mar 17, 2026 | |
| SYK Stryker | Maintains: Neutral | $400 → $380 | $329.01 | +15.50% | 8 | Mar 17, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $12 → $11 | $4.32 | +154.63% | 4 | Mar 6, 2026 | |
| RXST RxSight | Maintains: Neutral | $8 → $9 | $7.29 | +23.46% | 5 | Feb 26, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $19.82 | +11.00% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $29.04 | +89.39% | 14 | Feb 18, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $92.59 | -7.12% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $83.46 | +13.83% | 14 | Jan 12, 2026 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $55.07 | +65.24% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $122.07 | +18.78% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $24.09 | +157.37% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $82.92 | +23.01% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $188.31 | +112.42% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.92 | +204.69% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $14.31 | +11.81% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $61.41 | +54.70% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $18.49 | +13.57% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $470.99 | +27.39% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $225.34 | -5.03% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $24.54 | +132.27% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $92.80 | +59.48% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $5.48 | -58.94% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $4.40 | +18,671.33% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $39.39 | -64.46% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $84.11 | +18.89% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $17.25 | -30.43% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $36.98 | +21.69% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $150.22 | +83.06% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.39 | +736.82% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $7.25 | +479.31% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $7.27 | +725.31% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.61 | +2,350.98% | 1 | Sep 1, 2020 |
Boston Scientific
Mar 17, 2026
Maintains: Buy
Price Target: $120 → $105
Current: $59.95
Upside: +75.15%
Stryker
Mar 17, 2026
Maintains: Neutral
Price Target: $400 → $380
Current: $329.01
Upside: +15.50%
Sight Sciences
Mar 6, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $4.32
Upside: +154.63%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $7.29
Upside: +23.46%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $19.82
Upside: +11.00%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $29.04
Upside: +89.39%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $92.59
Upside: -7.12%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $83.46
Upside: +13.83%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $55.07
Upside: +65.24%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $122.07
Upside: +18.78%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $24.09
Upside: +157.37%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $82.92
Upside: +23.01%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $188.31
Upside: +112.42%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.92
Upside: +204.69%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $14.31
Upside: +11.81%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $61.41
Upside: +54.70%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $18.49
Upside: +13.57%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $470.99
Upside: +27.39%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $225.34
Upside: -5.03%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $24.54
Upside: +132.27%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $92.80
Upside: +59.48%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $5.48
Upside: -58.94%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $4.40
Upside: +18,671.33%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $39.39
Upside: -64.46%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $84.11
Upside: +18.89%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $17.25
Upside: -30.43%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $36.98
Upside: +21.69%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $150.22
Upside: +83.06%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.39
Upside: +736.82%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $7.25
Upside: +479.31%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $7.27
Upside: +725.31%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.61
Upside: +2,350.98%